Cite
MLA Citation
A. Kavanaugh et al.. “FRI0447 Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from A Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 1).” Annals of the rheumatic diseases, vol. 75, n.d., pp. 597–598. http://access.bl.uk/ark:/81055/vdc_100135159936.0x00004f